Park Square Financial Group’s Novo Nordisk NVO Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
Sell
-81
Closed -$6.97K 302
2025
Q4
$6.97K Buy
+81
New +$4.14K 0.04% 176
2025
Q3
Sell
-300
Closed -$20.7K 722
2025
Q2
$20.7K Sell
300
-9
-3% -$612 0.02% 449
2025
Q1
$21.5K Sell
309
-29
-9% -$2.4K 0.02% 423
2024
Q4
$29.1K Buy
+338
New +$36.6K 0.02% 358

Other funds holding NVO

Park Square Financial Group's NVO Position: Q1 2026 in Review

Park Square Financial Group sold out of Novo Nordisk (NVO) in Q1 2026, closing a stake of 81 shares — an estimated $6.97K sold.

Park Square Financial Group first reported a position in NVO in Q4 2024 and held it in 4 quarters. The position peaked at $29.1K in Q4 2024. 1,272 funds tracked by Wall St. Rank hold NVO as of Q1 2026.

  • Park Square Financial Group reported no remaining Novo Nordisk position as of Q1 2026 after selling out during the quarter.
  • Park Square Financial Group sold 81 Novo Nordisk shares in Q1 2026, an estimated $6.97K.
  • Park Square Financial Group first reported a position in Novo Nordisk in Q4 2024 and held it in 4 quarters.
  • Park Square Financial Group's Novo Nordisk position peaked at $29.1K in Q4 2024.
  • 1,272 funds tracked by Wall St. Rank held Novo Nordisk as of Q1 2026.

Based on Park Square Financial Group's 13F filing for Q1 2026, filed 13 May 2026.